Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P190032/S030

FoundationOne Liquid CDx (F1 Liquid CDx)

Foundation Medicine, Inc. · Decision date Aug 12, 2026

FDA DECISIONP190032/S030

What did the FDA approve?

FDA records P190032/S030 as a supplement to PMA P190032, with the supplement type “135 Review Track For 30-Day Notice”. The recorded decision is approval, dated Aug 12, 2026.

FDA approval order statement

approval for a change in the reagent manufacturing QC workflow
Regulatory pathway
PMA supplement
Supplement type
135 Review Track For 30-Day Notice
Clinical specialty
Pathology
Decision date
Aug 12, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P190032/S030
Regulatory pathway
PMA supplement
Product code
PQP
Decision code
APPR
Decision date
Aug 12, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.

Product code
PQP
FDA device class
3

For the original device and its historical approval scope, see PMA P190032. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P190032 · Original PMA

    FoundationOne Liquid CDx (F1 Liquid CDx)

  2. P190032/S030 received

    Application receipt date recorded by FDA.

  3. P190032/S025 · Related supplement

    FoundationOneLiquid CDx

  4. P190032/S029 · Related supplement

    FoundationOne Liquid CDx

  5. P190032/S030 · FDA decision

    135 Review Track For 30-Day Notice

  6. P190032/S032 · Related supplement

    FoundationOne Liquid CDx (F1LCDx)

Timeline entries are records held by MedtechLedger for P190032. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P190032

Product / regulatory recordCompanyPathwayDecision dateSource
Foundation Medicine, Inc.PMA approvalAug 26, 2020FDA
Foundation Medicine, Inc.PMA supplementMay 8, 2026FDA
Foundation Medicine, Inc.PMA supplementMay 27, 2026FDA
Foundation Medicine, Inc.PMA supplementSep 18, 2026FDA

Explore the linked device profile

Other records with product code PQP

Product / regulatory recordCompanyPathwayDecision dateSource
Life Technologies CorporationPMA supplementNov 4, 2026FDA
xT CDxP210011/S006
Tempus AI, Inc.PMA supplementOct 23, 2026FDA
MI Cancer SeekP240010/S007
Caris Life SciencesPMA supplementOct 16, 2026FDA
Guardant360 CDxP200010/S029
Guardant Health, Inc.PMA supplementSep 18, 2026FDA
FoundationOne CDxP170019/S069
Foundation Medicine, Inc.PMA supplementSep 16, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Foundation Medicine, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
400 Summer St., Boston, MA, 02210

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records